Julie Brittenden

• Deputy lead of division of applied medicine (2011-)
• University Academic lead for MHRA activites (2011)-Chair Clinical studies Oversight Group,  oversee that processes/SOPS/ structures  are in place to ensure compliance with regulations, provide medical advice when a SAE/ SUSAR/serious breech is notified, to contribute to the different groups established to ensure the highest quality CTIMPS 
• Clinical Advisor to CHART (2009-2010)-advise on the suitability of clinical trials and liaise between the unit and clinicians.
• Lead ofInstitute ofMedical Science Vascular research programmes (2006-), Division (2007-2009)
• Deputy lead: Cardiovascular research programme (2010-)
• Lead of NHS Vascular research programmes (2007-, Co-Lead 2005-2007)

My research interests are in cardiovascular biomarkers, platelet and endothelial function, plaque instability and the management of venous diseases.

National roles include: Member of the Research Council of the Vascular Society of Great Britain & Ireland, Council member of Venous Forum, Facualty Member of Charing Cross International Vascular Symposium, Advisor on NHS research priorities to HTA interventional procedures panel

I am Asessment co-ordinator for the Medical school, University of Aberdeen. 

National interests include: ¿member of the PLAB board ¿¿responsible for developing, analysing and reviewing assessment in medicine (2006-¿)¿¿;¿¿¿¿¿¿¿¿¿ ex¿¿ternal examin¿¿e¿r¿¿¿ for the final year medicine at the Universities of Leeds and Dundee.

 National interests include: Vascular Surgery Advisor to the Scottish Chief Medical Officer, member of the Scottish Medical and Advisory Committee, member of the Scottish National Aortic Aneurysm Screening Implementation Group and Work Delivery Group, Chairperson of SIGN guidelines on management of Venous ulcers and critiscm editor for Cochrane Peripheral arterial disease group

FRCS (Glasgow): 1994

MD with Honours (University of Aberdeen):1995

FRCS intercollegiate (Gold medal):2000

The main findings of our research to date are

1) Patients with peripheral arterial disease have a prothrombotic state which may predispose to their increased risk of cardiovascular morbidity and mortality

2) routine treatment such as surgery may exacebate this prothrombotic state and contribute to to the post-operative cardiovascular complications seen in these patients

3) Platelet activity increases with the severity of the disease suggesting the need for more aggresive anti-platelet therapy in patients with severe disease

4)Aspirin non-responsiveness increases post-operatively and predisposes to post-operative myocardial injury